ArticleFrontiers in immunology2022
Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.Emerging microbes & infections · 2026Article
- Protocol for precision cutting and short-term culture of lymph node tissue slices for modeling of innate immune responses ex vivo.STAR protocols · 2026Article
- Bivalent virus-like particles expressing SPECT1 and CSP trigger pre-erythrocytic malaria immunity and protect against transgenicFrontiers in immunology · 2026Article
- The challenge of one billion adjuvanted vaccine doses: evaluating scalability, sustainability, and supply capacity of Quillaja saponin QS-21 for large-scale vaccine demand.Frontiers in immunology · 2026Review
- Glioblastoma Immunotherapy Adjuvants for Glial Cell Polarization Regulation.Experimental neurobiology · 2025Review
- A Comparative Evaluation of Adjuvants for Enhancing Antibody Responses to a Nanoparticle-Based Malaria Vaccine.bioRxiv : the preprint server for biology · 2025Article
- Ex vivo model of functioning human lymph node reveals role for innate lymphocytes and stroma in response to vaccine adjuvant.Cell reports · 2025Article
- Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot.Science translational medicine · 2025Article
- Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.Scientific reports · 2025Article
- Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.Frontiers in immunology · 2025Article
- Development of semisynthetic saponin immunostimulants.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024Review
- Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice.Pharmaceutics · 2023Article
- Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults.Clinical and experimental immunology · 2023Review
- Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.Cell reports. Medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various chemical adjuvants are available to augment immune responses to non-replicative, subunit vaccines. Optimized adjuvant selection can ensure that vaccine-induced immune responses protect against the diversity of pathogen-associated infection routes, mechanisms of infectious spread, and pathways of immune evasion. In this study, we compare the immune response of mice to a subunit vaccine of Middle Eastern respiratory syndrome coronavirus (MERS-CoV) spike protein, stabilized in its prefusion conformation by a proprietary molecular clamp (MERS SClamp) alone or formulated with one of six adjuvants: either (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.